CORRESPONDENCE

Response to "The importance of determining the limit of detection of non-invasive prenatal testing methods"

We thank Dr Lüthgens and collaborators for their interest in our article.[1] We welcome the opportunity to provide clarification and further stimulate the discussion on this important topic.

The authors raised concerns regarding the accuracy of the method used in our study to determine the fetal fraction (FF). The reason for their criticism is related to the higher proportion of samples with an FF <4% reported in our article, compared with that observed in other studies.

Different approaches are currently available for estimating the FF, either from the isolated DNA[2–4] or the sequencing data.[5–8] Among these methods, no two are alike. Thus, it is not surprising that these approaches show a relatively high variation in FF values, even at similar mean gestational age or when comparing similar populations. Recently, Gil et al.,[9] in a meta-analysis of published studies, reported that the incidence of test failures due to low FF (<4%) ranged from 0.5 to 6.1%. For instance, Pergament et al.[10] described a 6.1% rate of the samples with FF <4% in a population of patients with a mean gestational age of 17.0 weeks ± 4.1 days. This value is not so different from that reported in our study (8.5%), involving a significantly lower mean gestational age (12.8 weeks ± 2.3 days).

Lüthgens and collaborators found in their clinical practice only 0.6% of samples with FF <4%, a proportion that is also much lower than expected if compared with the 2 to 5% observed in the studies cited by the authors. This finding may be explained by the specific method used for FF determination or the characteristics of the population under evaluation (e.g. higher mean gestational age or lower mean maternal weight, as compared with our study). Alternatively, it could be assumed that FF is overestimated with their method, although no definitive conclusions can be drawn from the authors' data set because such details have not been provided.

The aforementioned methods for FF determination have not been compared with the same set of samples nor validated using standard reference DNAs; therefore, it is not currently possible to define which approach works best.

In addition, each non-invasive prenatal testing (NIPT) approach uses a different bioinformatics method to compute aneuploidy risk, their own protocol for FF estimation, and different sequencing depths (i.e. the number of sequence tags counted for each chromosome tested). The combination of such parameters characterizes the limit of detection (LOD; i.e. the lowest FF with a detectable aneuploidy), which is different for each specific NIPT approach. Therefore, several NIPT protocols may need a minimum FF level of 4%. Other methods may be able to reliably detect aneuploidies at a lower FF, because they involve a higher sequencing depth or a more sensitive bioinformatics analysis.[11]

Lüthgens and collaborators believe that setting a lower threshold for FF below 4% will necessarily affect the sensitivity of the cell-free fetal DNA (cfDNA) testing. However, this assumption does not take into consideration the fact that the reliability of cfDNA testing results depends not only on the FF level but also on the sequencing depth employed in testing,[12] both impacting the sensitivity or specificity of the cfDNA assay. If there is a low FF in the sample and a sufficiently high sequencing depth, then the assay can still provide accurate counting of the available chromosome fragments. The higher the number of sequence tags counted, the better the ability to distinguish euploid from aneuploid fetuses, thereby the better the test performance.

Recently, Benn and Cuckle[13] demonstrated that a low FF can partly be compensated by a higher sequencing depth, and the number of generated reads may thus overcome the statistical noise. In fact, when either depth or fetal fraction is high, expected cfDNA-based aneuploidy screening detection rates are high. However, when FF is low, deeper sequencing (at least ten millions of tags) is required to obtain high detection rates.

The NIPT protocol used in our study relied on a high sequencing depth (an average of 16 ± 1.6 millions of unique tags). Such a level of resolution was sufficient to reliably detect aneuploidies in samples with low FF. This was demonstrated by the results of the LOD experiments and confirmed by the chromosomally abnormal pregnancies involving a 2% < FF < 4%, which were consistently identified, with no false negative results. It is unlikely that the two false positive cases that occurred in our study could be related with the low FF, as assumed by the authors. In fact, a low FF may potentially decrease the detection rate (or

sensitivity), and it is unlikely to have much impact on the false positive.

Lüthgens and collaborators also raised concerns on the size of samples included in the $2\% < FF < 4\%$ group. We recognize that such number is not high; however, the aim of our study was not to compare the cfDNA testing performance in samples with $2\% < FF < 4\%$ versus $FF \geq 4\%$. In fact, we aimed to demonstrate that each specific NIPT approach should use an FF cut-off related with its actual LOD and not a fixed value that is too low or too high. Nevertheless, updated data with follow-up from our study, involving a cohort of 16 856 samples, may be helpful in addressing the authors' criticisms. Out of 8540 pregnancies with a male fetus, 25/570 samples with $2\% < FF < 4\%$ and 89/7970 with $FF \geq 4\%$ were chromosomally abnormal. The sensitivity was 100% for both the $2\% < FF < 4\%$ group (95% CI 86.35–100%) and $FF \geq 4\%$ (95% CI 95.94–100%). Two false positive cases resulted in the $2\% < FF < 4\%$ group and one in the $FF \geq 4\%$ group, with a specificity of 98.63% (95% CI 98.7–99.96%) and 99.99% (95% CI 99.93–100%), respectively. Therefore, our updated data still indicate that lowering the FF threshold below 4% did not decrease the accuracy of cfDNA screening.

Finally, Lüthgens and collaborators raised concerns on the incidence of pregnancies with trisomy (T) 21 in the $2\% < FF < 4\%$ group compared with the euploid pregnancies in the same cohort of samples. In our data set of pregnancies with $2\% < FF < 4\%$, those with euploid results had an average FF of $2.8\% \pm 0.04$, while those with T21 had an average of $3.1\% \pm 0.03$. In the group with $FF \geq 4\%$, euploid pregnancies had an average FF of $9.7\% \pm 0.04$, while those with T21 had $10.9\% \pm 0.04$. Therefore, the mean FF for fetuses with T21 was higher than for euploid male fetuses. In addition, considering the entire cohort of patients, the FF was higher in pregnancies with T21 ($9.9\% \pm 0.04$) compared with T18 ($6.6\% \pm 0.04$) and T13 ($5\% \pm 0.034$), thus confirming the data reported in the literature.

In conclusion, we strongly feel that the minimum FF level necessary for accurate aneuploidy assessment should be related to the actual LOD of each specific NIPT approach used and not necessarily fixed at 4% for all cfDNA testing methodologies. The determination of the LOD represents a basic quality metric advisable for any NIPT method, which is required to ensure that the appropriate FF cut-off value can be used.

Francesco Fiorentino*, Sara Bono, Francesca Pizzuti, Martina Mariano, Arianna Polverari, Sara Duca, Mariateresa Sessa, Marina Baldi, Laura Diano and Francesca Spinella

GENOMA Molecular Genetics Laboratory, Rome, Italy
*Correspondence to: Francesco Fiorentino. E-mail: fiorentino@laboratoriogenoma.it

REFERENCES

1. Fiorentino F, Bono S, Pizzuti F, *et al.* The importance of determining the limit of detection of non invasive prenatal testing methods. Prenat Diagn 2016;36:304–11.
2. Nygren AOH, Dean J, Jensen TJ, *et al.* Quantification of fetal DNA by use of methylation-based DNA discrimination. Clin Chem 2010;56:1627–35.
3. Bruno DL, Ganesamoorthy D, Thorne NP, *et al.* Use of copy number deletion polymorphisms to assess DNA chimerism. Clin Chem 2014;60:1105–14.
4. Lun FM, Chiu RW, Chan KC, *et al.* Microfluidics digital PCR reveals a higher than expected fraction of fetal DNA in maternal plasma. Clin Chem 2008;54:1664–72.
5. Sparks AB, Struble CA, Wang ET, *et al.* Noninvasive prenatal detection and selective analysis of cell-free DNA obtained from maternal blood: evaluation for trisomy 21 and trisomy 18. Am J Obstet Gynecol 2012;206:319.e1–9.
6. Dar P, Curnow KJ, Gross SJ, *et al.* Clinical experience and follow-up with large scale single-nucleotide polymorphism-based noninvasive prenatal aneuploidy testing. Am J Obstet Gynecol 2014;211:527.e1–17.
7. Rava RP, Srinivasan A, Sehnert AJ, *et al.* Circulating fetal cell-free DNA fractions differ in autosomal aneuploidies and monosomy X. Clin Chem 2014;60:243–50.
8. Fan HC, Blumenfeld YJ, Chitkara U, *et al.* Noninvasive diagnosis of fetal aneuploidy by shotgun sequencing DNA from maternal blood. Proc Natl Acad Sci 2008;105:16266–71.
9. Gil MM, Quezada MS, Revello R, *et al.* Analysis of cell-free DNA in maternal blood in screening for fetal aneuploidies: updated meta-analysis. Ultrasound Obstet Gynecol 2015;45:249–66.
10. Pergament E, Cuckle H, Zimmermann B, *et al.* Single-nucleotide polymorphism-based noninvasive prenatal screening in a high-risk and low-risk cohort. Obstet Gynecol 2014;124:210–8.
11. Yaron Y. The implications of non-invasive prenatal testing failures: a review of an under-discussed phenomenon. Prenat Diagn 2016;36:391–6.
12. Fan HC, Quake SR. Sensitivity of noninvasive prenatal detection of fetal aneuploidy from maternal plasma using shotgun sequencing is limited only by counting statistics. PLoS One 2010;5:e10439.
13. Benn P, Cuckle H. Theoretical performance of non-invasive prenatal testing for chromosome imbalances using counting of cell-free DNA fragments in maternal plasma. Prenat Diagn 2014;34:778–83.

CORRESPONDENCE

Comment on "The importance of determining the limit of detection of non-invasive prenatal testing methods"

With interest, we read the article by Fiorentino *et al.* suggesting that fetal aneuploidies are reliably detectable by cell-free DNA (cfDNA) analysis in maternal plasma at a fetal fraction (FF) threshold lower than the commonly accepted limit of 4%.[1] Fiorentino *et al.* present an experimental model constructing samples in their laboratory to contain an FF range from 4% to 1%. They then present the results of analysis in maternal plasma samples with an FF estimated to be as low as 2%. Despite previous modeling showing that a lower FF decreases the accuracy of cfDNA screening,[2] the investigators conclude that an FF between 2% and 4% allows consistent detection of aneuploidies and propose that a limit of detection may be individually determined for different testing methodologies.

We agree that the use of a minimum threshold for FF is a critical component in assay performance and find this study an interesting effort to determine this experimentally with an untargeted methodology. However, the data presented in this paper raise concerns about the underlying methods and data analysis upon which the authors' conclusions are based.

The first question centers on the accuracy of FF measurement. The investigators utilize a published method of MPS tag-count data of X chromosome and aneuploid chromosome ratios in pregnancies with a male fetus[3], however, the study reports data related to FF that are, to our knowledge, inconsistent with previous investigations. Overall, 8.5% of clinical samples in this study had an FF lower than 4%. This is a higher proportion than expected compared with the 2–5% observed in previous studies with comparable gestational age ranges.[4–7] The targeted NIPT method used by our laboratory is showing an even lower rate of samples with an FF below 4%: in more than 20 000 unselected routine samples, the rate of samples with an FF below 4% is only 0.6%. Thus, the argument that cases of aneuploidy are missed when results are not given if the FF is <4% is of limited relevance in our population. Furthermore in our experience, these cases usually undergo re-testing by NIPT or other alternative methods of screening for trisomy. We are also surprised by the 22% (17/76) of trisomy 21 pregnancies with an FF between 2% and 4%. This suggests that the FF in trisomy 21 pregnancies is lower than in euploid pregnancies in this cohort. The currently existing literature supports a correlation between lower FF and trisomy 18 and 13 but not trisomy 21.[3,8–10]

The second question is related to test performance. Although over 7000 women were enrolled in the study, it is only the 231 male samples with an FF between 2% and 4% that are most relevant for assessment of test performance at lower FF. The 25 aneuploid samples in this group are certainly not a large enough sample size to demonstrate equivalent clinical sensitivity to that obtained with FF greater than 4%. Likewise, the sample size is not large enough to address specificity; however, it is notable that both false positive results occurred in the 2% to 4% FF group. Ignoring the abovementioned question about accuracy of FF measurement, the small sample size does not allow performance calculations in the proposed 2–4% FF strata that are within levels of random variation such that can be trusted to change practice in clinical settings.

In summary, if accurately measured, it is theoretically possible to set a lower threshold for FF below 4%, but this lowering will necessarily come at the expense of sensitivity. Based on these questions about FF measurement and lack of statistical power in this investigation, we suggest that this proposal to lower the minimum threshold for FF be approached with caution and with a warning about the potential loss of sensitivity.

Kai Lüthgens[1], Andreas Binder[1] and Dirk Biskup[2]

[1]Cenata GmbH, Paul-Ehrlich-Str. 23, D-72076 Tübingen, Germany
[2]CeGaT, Paul-Ehrlich-Str. 23, D-72076 Tübingen, Germany
*Correspondence to: Kai Lüthgens. E-mail: luethgens@labor-enders.de

REFERENCES

1. Fiorentino F, Bono S, Pizzuti F, *et al.* The importance of determining the limit of detection of non invasive prenatal testing methods. Prenat Diagn 2016;36:304–11, DOI: 10.1002/pd.4780.
2. Canick JA, Palomaki GE, Kloza EM, *et al.* The impact of maternal plasma DNA fetal fraction on next generation sequencing tests for common fetal aneuploidies. Prenat Diagn 2013;33:667–74.
3. Rava RP, Srinivasan A, Sehnert AJ, *et al.* Circulating fetal cell-free DNA fractions differ in autosomal aneuploidies and monosomy X. Clin Chem 2014;60:243–50.
4. Wang E, Batey A, Struble C, *et al.* Gestational age and maternal weight effects on fetal cell-free DNA in maternal plasma. Prenat Diagn 2013;33:662–6.

5. Norton ME, Jacobsson B, Swamy GK, *et al*. Cell-free DNA analysis for noninvasive examination of trisomy. N Engl J Med 2015;372: 1589–97.

6. Kinnings S, Geis J, Almasri E, *et al*. Factors affecting levels of circulating cell-free fetal DNA in maternal plasma and their implications for noninvasive prenatal testing. Prenat Diagn 2015;35:816–22.

7. Dar P, Curnow KJ, Gross SJ, *et al*. Clinical experience and follow-up with large scale single-nucleotide polymorphism-based noninvasive prenatal aneuploidy testing. Am J Obstet Gynecol 2014;211:527.e1–e527.e17.

8. Ashoor G, Syngelaki A, Poon LCY, *et al*. Fetal fraction in maternal plasma cell-free DNA at 11–13 weeks' gestation: relation to maternal and fetal characteristics. Ultrasound Obstet Gynecol 2013;41:26–32.

9. Palomaki GE, Kloza EM, Lambert-Messerlian GM, *et al*. Circulating cell free DNA testing: are some test failures informative? Prenat Diagn 2015;35:289–93.

10. Revello R, Sarno L, Ispas A, *et al*. Screening for trisomies by cell-free DNA testing of maternal blood: consequences of failed result. Ultrasound Obstet Gynecol 2016, DOI: 10.1002/uog.15851.